AEVIS VICTORIA SA / Key word(s): Miscellaneous AEVIS VICTORIA SA – Fabrice Zumbrunnen joins the Board of Directors of Swiss Medical Network SA 06.07.2023 / 07:00 CET/CEST Press release Fribourg, 6 July 2023 AEVIS VICTORIA SA (AEVS:SW) – Fabrice Zumbrunnen joins the Board of Directors of Swiss Medical Network SA Fabrice Zumbrunnen, a prominent and leading Swiss personality, has joined the Board of Directors of Swiss Medical Network SA, the second largest private hospital and clinic group in Switzerland, subsidiary of AEVIS VICTORIA. Fabrice Zumbrunnen (age 53) graduated in economics from the University of Neuchâtel and has spent a large part of his career within Migros Group, including the last five years as CEO. He has also chaired or represented numerous group companies on their Boards of Directors, including Digitec Galaxus, Denner, Globus, Migros Bank and Hotelplan. Fabrice Zumbrunnen moreover played a key role in shaping Migros’ medical strategy, which was initiated in 2001 with the acquisition of Medbase, and has since then been successfully developed. According to Raymond Loretan, Chairman of the Board of Directors of Swiss Medical Network, Fabrice Zumbrunnen will contribute to further enhancing the integrated care strategy, which began last autumn with the constitution of Réseau de l’Arc, the first fully integrated healthcare organization in the Jura Arc region, laying the foundations for a genuine paradigm shift in the Swiss healthcare system. Christian Le Dorze is stepping down from the Board of Directors after more than 12 years, and will devote himself to new healthcare projects in France and Europe. The Board of Directors of Swiss Medical Network expresses its sincere gratitude to Christian Le Dorze for his outstanding commitment. For further information: AEVIS VICTORIA SA – Investing for a better life End of Media Release |
Sanofi reports sales jump for Beyfortus as RSV antibody challenger from Merck nears
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS